MASON, Ohio, April 2, 2013 /PRNewswire/ -- AssureRx Health, Inc. today announced the appointment of Stephen A. Stamp as Senior Vice President & CFO and Jeffrey P. Bush as Vice President, Payer Markets and Reimbursement to its leadership team. The management appointments coincide with increasing demand for GeneSight pharmacogenomic testing services, which support healthcare providers in medication selection and the management of side effects for patients with neuropsychiatric and other disorders.
"These management appointments provide us with the financial leadership to address the next phase of our growth strategy and the payer market expertise to partner with Medicare, Medicaid, and commercial payers," said James S. Burns , president and CEO of Assurex Health. "Our value proposition is directed to demonstrating significant improvements in patient outcomes at substantial reductions in healthcare utilization. The goal is to build the leading personalized medicine company offering pharmacogenomic treatment decision support solutions for neuropsychiatric, pain, ADHD, and other disorders."
Stephen A. Stamp , Senior Vice President & Chief Financial Officer is responsible for all financial matters at Assurex Health, including financing strategy and implementation, accounting, tax, M&A activities, and government contracting. Stephen joins Assurex Health with 30 years of experience in finance, accounting, business development and operations. He has worked in multiple public and venture-backed companies both in the US and the UK, including business to consumer (B2C), business to business (B2B), and pharmaceutical industries. Stephen has served as Chief Financial Officer of EZCORP, Inc. (NASDAQ: EZPW), a consumer financial services company; Chief Operating Officer, Chief Financial Officer, and Executive Vice President Business Development at Xanodyne Pharmaceuticals, Inc., a specialty pharmaceutical company; Group Finance Director at Regus PLC, a serviced office accommodations business; and Group Finance Director at Shire PLC, a specialty pharmaceutical company focusing on ADHD and other specialty medications. Earlier in his career, Stephen was an investment banker with Lazard in London, advising mainly public companies on cross-border M&A and corporate finance. Prior to Lazard, he worked for KPMG in London where he qualified as a Chartered Accountant. Stephen received his BA in economics from the University of Manchester.
Jeffrey P. Bush , Vice President of Payer Markets and Reimbursement is responsible for establishing coverage and value-based reimbursement with commercial and governmental payers for Assurex Health products, as well as the Company's overall strategy for collaborating with payers and payer stakeholders. Jeff brings to Assurex Health over twenty years of experience in diagnostics, medical devices, and clinical laboratory testing. Prior to joining Assurex Health, Jeff served as senior director of Reimbursement Strategy & Payment Policy at Becton, Dickinson and Company (BD) (NYSE: BDX), a global medical device and diagnostic system manufacturer, responsible for reimbursement across BD's three worldwide business segments to establish coding, coverage, and payment for the company's products in the US and abroad. While at BD, Jeff was instrumental in the development and passage of reform legislation that enhanced transparency of the Centers for Medicare and Medicaid Services (CMS) processes for the coverage and payment of new diagnostic technologies, and developed quality measurement legislative language included in the Affordable Care Act of 2010. Prior to BD, Jeff led CYTYC Corporation's (now Hologic) efforts with US payers that drove adoption and eventual market dominance of the ThinPrep® Pap Test. Prior to CYTYC, Jeff was employed as a certified cytotechnologist in multiple clinical laboratories. He holds a Bachelor's degree in Chemistry from California State University, San Bernardino, a Cytotechnology certificate from Loma Linda University, and a Master of Business Administration from Colorado State University.
About AssureRx Health, Inc.
AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenomics dedicated to helping physicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Mayo Clinic and Cincinnati Children's Hospital Medical Center are equity holders and technology collaborators.
GeneSight is a laboratory developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient's unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual's response to drug treatments, FDA approved manufacturer's drug labels, peer-reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient's genomic makeup, clinical experience and other factors can help a physician make personalized drug treatment choices for each patient.
|SOURCE AssureRx Health, Inc.|
Copyright©2012 PR Newswire.
All rights reserved